PA8657301A1 - Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento - Google Patents

Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento

Info

Publication number
PA8657301A1
PA8657301A1 PA20058657301A PA8657301A PA8657301A1 PA 8657301 A1 PA8657301 A1 PA 8657301A1 PA 20058657301 A PA20058657301 A PA 20058657301A PA 8657301 A PA8657301 A PA 8657301A PA 8657301 A1 PA8657301 A1 PA 8657301A1
Authority
PA
Panama
Prior art keywords
disorders
triazolona
tetrazolona
imidazolona
medicinal product
Prior art date
Application number
PA20058657301A
Other languages
English (en)
Inventor
Mauel Jesus Alcazar-Vaca
Jose Ignacio Andres-Gil
Joaquim Pastor-Fernandez
Wilhwlmus Helena Ignatius Maria Drinkenburg
Xavier Jean Michel Langlois
Santamariana Julen Oyarzabal
Juan Antonio Vega-Ramiro
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8657301A1 publication Critical patent/PA8657301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

LA PRESENTE INVENCION CONCIERNE A DERIVADOS SUSTANTIVOS DE TRIAZOLONA, TETRAZOLONA E IMIDAZOLONA DE ACUERDO CON LA FORMULA (I) UNA SAL DE ADICION CON ACIDO O BASE ACEPTABLE PARA USO FARMACEUTICO DEL MISMO, UNA FORMA ESTEREOQUIMICAMENTE ISOMERICA DEL MISMO, UNA FORMA N-OXIDO DEL MIMO O UNA SAL DE AMONIO CUATERNARIO DEL MISMO, DONDE LAS VARIABLES SE DEFINEN EN LA REIVINDICACION 1, QUE TIENEN ACTIVIDAD ANTAGONISTA SELECTIVA DEL ALFA 2C-ADRENORECEPTOR. TAMBIEN SE REFIERE SU PREPARACION, A COMPOSICIONES QUE LOS COMPRENDEN Y A SU USO COMO MEDICAMENTO. LOS COMPUESTOS DE ACUERDO CON LA INVENCION SON UTILES PARA LA PREVENCION Y/O TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS DEL HUMOS, TRASTORNOS DE ANSIEDAD,TRASTORNOS DEL HUMOR, TRASTORNOS RELACIONADOS DON EL ESTRES ASOCIADOS CON DEPRESION Y/O ANSIEDAD, TRASTORNOS COGNITIVOS, TRASTORNOS DE LA PERSONALIDAD, TRASTORNOS ESQUIZOAFECTIVOS, ENFERMEDAD DE PARKINSON, DEMENCIA DE TIPO ALZHEIMER, AFECCIONES DE DOLOR CRONICO, ENFERMEDAD NEURODEGENERATIVAS, TRASTORNOS DE ADICCION, TRASTORNOS DEL HUMOR Y DISFUNCION SEXUAL.
PA20058657301A 2004-12-21 2005-12-20 Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento PA8657301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106817 2004-12-21
EP05104873 2005-06-03

Publications (1)

Publication Number Publication Date
PA8657301A1 true PA8657301A1 (es) 2007-01-17

Family

ID=36013649

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058657301A PA8657301A1 (es) 2004-12-21 2005-12-20 Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento

Country Status (15)

Country Link
US (1) US20100029620A1 (es)
EP (1) EP1831185A1 (es)
JP (1) JP2008524312A (es)
KR (1) KR20070090941A (es)
AR (1) AR052342A1 (es)
AU (1) AU2005318188A1 (es)
BR (1) BRPI0516380A (es)
CA (1) CA2588028A1 (es)
EA (1) EA011514B1 (es)
IL (1) IL184048A0 (es)
MX (1) MX2007007472A (es)
NO (1) NO20073760L (es)
PA (1) PA8657301A1 (es)
TW (1) TW200635906A (es)
WO (1) WO2006067139A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2012043791A1 (ja) * 2010-10-01 2012-04-05 大正製薬株式会社 １，２，４-トリアゾロン誘導体
FR2976287B1 (fr) 2011-06-09 2013-07-05 Pf Medicament Derives benzoquinolizidines, leur procede de preparation et leurs applications en therapeutique
MY168930A (en) * 2011-10-27 2019-01-09 Taisho Pharmaceutical Co Ltd Azole derivative
EP2852589B1 (en) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
EP3008055B1 (en) * 2013-06-11 2017-07-19 F. Hoffmann-La Roche AG Tetrazolone derivatives
KR20160026897A (ko) * 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
US20190297887A1 (en) 2016-07-12 2019-10-03 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
CA3185336A1 (en) * 2017-11-06 2019-05-09 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3355457A (en) * 1965-05-21 1967-11-28 American Cyanamid Co Substituted 2-imidazolinones
DE2725148A1 (de) * 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
PT741737E (pt) * 1994-01-24 2000-04-28 Janssen Pharmaceutica Nv Antifungicos do tipo azole soluveis em agua
JPH0899975A (ja) * 1994-08-05 1996-04-16 Nippon Bayeragrochem Kk ５員複素環置換テトラゾリノン誘導体および除草剤
JPH09183770A (ja) * 1995-10-31 1997-07-15 Nippon Bayeragrochem Kk １−アジン−テトラゾリノン類及び除草剤
AU5519098A (en) * 1996-12-13 1998-07-03 E.I. Du Pont De Nemours And Company Herbicidal heterocyclic amides
WO1998051683A1 (en) * 1997-05-15 1998-11-19 E.I. Du Pont De Nemours And Company Herbicidal tetrazolinones
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
WO2000010984A1 (fr) * 1998-08-19 2000-03-02 Hokko Chemical Industry Co., Ltd. Derives de triazolinone et compositions herbicides
JP3837242B2 (ja) * 1998-08-25 2006-10-25 北興化学工業株式会社 トリアゾリノン誘導体および除草剤

Also Published As

Publication number Publication date
BRPI0516380A (pt) 2008-09-02
WO2006067139A1 (en) 2006-06-29
CA2588028A1 (en) 2006-06-29
MX2007007472A (es) 2007-07-20
IL184048A0 (en) 2007-10-31
JP2008524312A (ja) 2008-07-10
TW200635906A (en) 2006-10-16
EA011514B1 (ru) 2009-04-28
NO20073760L (no) 2007-07-19
AU2005318188A1 (en) 2006-06-29
AR052342A1 (es) 2007-03-14
EA200701345A1 (ru) 2007-10-26
EP1831185A1 (en) 2007-09-12
US20100029620A1 (en) 2010-02-04
KR20070090941A (ko) 2007-09-06

Similar Documents

Publication Publication Date Title
PA8657301A1 (es) Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
MX2020003552A (es) Formas cristalinas.
AR093490A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
PA8585001A1 (es) Compuestos de tiazol para el tratamiento de transtornos neurodegenerativos
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CL2020000747A1 (es) Formulaciones de niraparib.
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
DOP2010000261A (es) Derivados biciclicos heterociclicos o espirobicicicos heterociclicos enlazados , de pirazolo[1,5-a] pirimidinas, procedimientos para su preparacion y usos de los mismos
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
DK2091942T3 (da) Substituerede pyrazinderivater til anvendelse som en medicin
UY31387A1 (es) 5,6-diarilpiridinas sustituidas en posicion 2 y 3, su preparacion y su aplicacion terapéutica
EA201101579A1 (ru) Имидазо[1,2-а]пиридин-2-ил-фенил производные для лечения рака
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
NO20084819L (no) Substituerte pyrazinonderivater for anvendelse som en medisin
BR112014011262A8 (pt) compostos substituídos de carboxamida à base de pirazolila substituída e derivados de ureia, seus usos, e composição farmacêutica
IL192240A0 (en) Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
AR125919A2 (es) Formas de dosificación de ruxolitinib de liberación sostenida
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ